RT Journal Article
SR Electronic
T1 Distinct Plasma Protein Profiles Distinguish Faster from Slower Disease Progression in HIV-1 and HIV-2 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310457
DO 10.1101/2024.07.23.24310457
A1 Johansson, Emil
A1 Nazziwa, Jamirah
A1 Freyhult, Eva
A1 Hong, Mun-Gwan
A1 Neptin, Malin
A1 Karlson, Sara
A1 Rezeli, Melinda
A1 da Silva, Zacarias J.
A1 Biague, Antonio J.
A1 Lindman, Jacob
A1 Palm, Angelica
A1 Medstrand, Patrik
A1 Månsson, Fredrik
A1 Norrgren, Hans
A1 Jansson, Marianne
A1 Esbjörnsson, Joakim
A1 the SWEGUB CORE group
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310457.abstract
AB The asymptomatic disease stage in HIV-2 infection is approximately twice as long compared to in HIV-1 infection, still the majority of HIV-2 infected individuals progress to AIDS in the absence of antiretroviral treatment. In this study, we applied data-independent acquisition mass spectrometry analysis of blood plasma samples collected from HIV negative, and HIV-1 or HIV-2 infected individuals in Guinea-Bissau with an estimated date of HIV infection, to explore associations between plasma proteome alterations and HIV disease progression. In total, 609 proteins were quantified and mapped towards publicly available data on tissue-enhanced genes, to provide insight on the tissue-specific origin of the detected proteins. Here we identified ten proteins that could differentiate between faster and slower HIV disease progression. The analysis also suggested a larger leakage of proteins from the sigmoid colon in HIV-1 compared to HIV-2 infection. Moreover, the levels of sigmoid colon and spleen tissue proteins were associated with disease progression among all HIV infected individuals. In conclusion, these results encourage further research on the role of both target and bystander cells in HIV disease progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Swedish Research Council (grant number 2020-06262 to J.E; 2016-02285, 2019-01439 to M.J.) and by The Swedish Fund for Research without Animal Experiments to MJ (N2019-0009, F2021-0010).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical committee at Lund University gave ethical approval for this work The National Ethical Committee, Ministry of Public Health in Guinea-Bissau, gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUpon publication all codes will be made available at the systems virology GitHub website and the data will be uploaded to an appropriate repository.